Faster Insulins Cut Post-Meal Spikes — What You Need to Know

What Was Studied — and Why It Matters

Controlling blood sugar after meals is one of the hardest challenges for people with diabetes. Even standard "rapid-acting" insulin can lag behind the rise in blood sugar that follows eating. A new generation of ultra-rapid-acting insulins (URAIs) — including faster aspart (Fiasp) and ultra-rapid lispro (Lyumjev) — are designed to work faster. But do they actually deliver better results in real-world trials? Researchers pooled data from 12 clinical studies to find out.

What the Research Found

The meta-analysis, published in Diabetes Technology & Therapeutics (2024), compared ultra-rapid insulins to conventional rapid-acting insulins in people with both Type 1 and Type 2 diabetes. Here is what the data showed:

• Better post-meal blood sugar control: People with Type 1 diabetes saw blood sugar drop about 20 mg/dL more in the first hour after meals when using ultra-rapid insulin. People with Type 2 diabetes saw a roughly 9 mg/dL improvement in that same window.
• Longer benefit for Type 1: The improvement in blood sugar was still meaningful at the two-hour mark for people with Type 1 diabetes, but not as clearly for Type 2.
• Slight long-term HbA1c improvement: After one full year, people using ultra-rapid insulin had a small but real reduction in their HbA1c — a measure of average blood sugar over three months — compared to those on standard rapid-acting insulin.
• No extra low blood sugar episodes overall: There was no increase in serious or confirmed hypoglycemia (dangerously low blood sugar) for either group overall.
• One caution for Type 1: People with Type 1 diabetes did show a small increase in low blood sugar events in the first hour after injection — a reminder that timing matters.
• No weight difference: Switching to ultra-rapid insulin did not cause weight gain compared to standard options.

The Critical Detail: Timing Is Everything

All of these benefits only applied when the insulin was taken at mealtime. When ultra-rapid insulin was injected after eating, the advantages disappeared entirely. If you are prescribed one of these newer insulins, talk with your care team about the right moment to inject — typically right as you begin your meal or just before.

What This Means for Real Patients

If you are already managing mealtime insulin doses, switching to an ultra-rapid formula could help smooth out those frustrating post-meal blood sugar peaks — particularly if you have Type 1 diabetes. The research suggests the benefit grows the longer you use it, with the clearest HbA1c improvement showing up at the one-year mark.

Managing insulin effectively also means having reliable supplies on hand. MDS Diabetes carries a full range of insulin syringes, pen needles, and glucose monitoring supplies so you are always prepared for your routine — whatever insulin your doctor prescribes.

Bottom Line

Ultra-rapid-acting insulins like Fiasp and Lyumjev do a meaningfully better job of controlling blood sugar in the hour or two after meals compared to standard rapid-acting insulins — and they do it without increasing dangerous low blood sugar events or causing weight gain. The key is taking them at the right time: at the start of your meal, not after. Speak with your doctor or diabetes educator to find out whether making the switch makes sense for your situation.